10.6 Neonatal Jaundice — Recognition & Evaluation

Bedside Priority

Never assume physiologic until you have ruled out pathologic

Jaundice in the first 24 hours, rapidly rising bilirubin, signs of acute bilirubin encephalopathy, suspected hemolysis, prolonged jaundice, pale stools, dark urine, or any conjugated hyperbilirubinemia should be treated as abnormal until proven otherwise.

Do not estimate severity by skin color alone.

1. Purpose and Scope

This chapter standardizes recognition and evaluation of neonatal jaundice in term, late-preterm, and preterm infants. It focuses on pathophysiology, bedside risk stratification, differential diagnosis, laboratory workup, and escalation triggers. Treatment thresholds, phototherapy delivery, IVIG, and exchange transfusion workflow are covered in Chapter 10.7.

Applies to all infants with visible jaundice, elevated TcB, elevated TSB, suspected hemolysis, or prolonged jaundice.
Use hour-specific, gestation-specific treatment charts for therapeutic decisions; do not rely on visual inspection or non-validated thresholds.
For infants <35 weeks, use local NICU-specific preterm bilirubin charts and neonatal consultant review — AAP 2022 thresholds apply to infants ≥35 weeks only.

2. Working Definitions

Term	Clinical Meaning
Physiologic jaundice	Transient unconjugated hyperbilirubinemia caused by high bilirubin production, immature conjugation, and increased enterohepatic circulation. Typically peaks around days 2–5 in term/late-preterm infants and resolves over the next 2–3 weeks. It is a diagnosis of exclusion.
Significant hyperbilirubinemia	A bilirubin level that is high for postnatal age and gestational age, close to a treatment threshold, or associated with risk factors. Use the appropriate nomogram/chart rather than a single absolute number.
Severe / extreme hyperbilirubinemia	Baylor defines severe as TSB >25 mg/dL and extreme as TSB >30 mg/dL — both associated with increased risk of bilirubin-induced neurologic dysfunction (BIND).
Bilirubin-induced neurologic dysfunction (BIND)	A spectrum of neurologic injury caused by free bilirubin entering the brain, ranging from acute bilirubin encephalopathy to chronic kernicterus.
Acute bilirubin encephalopathy	Early Poor feeding, lethargy, high-pitched cry or mild tone abnormality. Intermediate Irritability, fever, moderate hypertonia or retrocollis/opisthotonos. Advanced Apnea, seizures, coma, or persistent posturing.
Cholestatic jaundice	Jaundice with elevated direct/conjugated bilirubin. This is never physiologic and requires evaluation for biliary, infectious, metabolic, endocrine, anatomic, and PN-related causes.

3. Why Bilirubin Rises in Newborns

Mechanism	Bedside Interpretation
Increased production	Newborns have higher hematocrit and shorter red-cell lifespan than older children. Hemolysis, bruising, cephalohematoma, polycythemia, and infection can markedly increase bilirubin load.
Reduced conjugation / clearance	Immature hepatic uptake and UGT1A1 activity reduce bilirubin conjugation. Prematurity, illness, endocrine disorders, galactosemia, and genetic disorders can worsen clearance.
Increased enterohepatic circulation	Delayed stooling, poor intake, dehydration, ileus, obstruction, or intestinal dysmotility increases reabsorption of bilirubin from the gut.
Reduced albumin binding	Prematurity, acidosis, sepsis, hypoxia, low albumin, and bilirubin-displacing drugs increase the unbound bilirubin fraction and neurotoxicity risk.
Conjugated hyperbilirubinemia	Represents impaired bile formation, hepatocellular disease, bile-duct obstruction, infection, endocrine/metabolic disease, or PN-associated cholestasis — not physiologic jaundice.

4. Risk Assessment at the Bedside

Risk Domain	What to Look For
Early timing	Visible jaundice in the first 24 hours is pathologic until evaluated; obtain serum bilirubin urgently and assess for hemolysis, sepsis, bruising, and other disease.
Lower gestational age	Each week below 40 weeks increases risk; preterm infants also have lower albumin binding and different treatment thresholds.
Hemolysis	Positive DAT, maternal RBC antibodies, ABO/Rh/minor-antigen disease, G6PD deficiency, hereditary spherocytosis, elliptocytosis, pyruvate kinase deficiency, or rapidly rising bilirubin.
Family / ethnic history	Sibling requiring phototherapy or exchange transfusion, known RBC disorder, ancestry associated with G6PD deficiency, or prior neonatal jaundice complications.
Feeding and hydration	Exclusive breastfeeding with suboptimal intake, excessive weight loss, delayed stooling, poor urine output, or dehydration.
Other contributors	Scalp hematoma or bruising, infant of diabetic mother, Down syndrome, infection, hypothyroidism, hypopituitarism, intestinal obstruction, or prolonged PN.
Neurotoxicity risk	Clinical instability, sepsis, acidosis, hypoxia, low albumin, hemolysis, or signs of acute bilirubin encephalopathy lower the safety margin — treat at lower thresholds.

Do not miss hemolysis

A rapidly rising bilirubin, early jaundice, anemia, reticulocytosis, positive DAT, known maternal antibody, G6PD risk, or poor response to phototherapy should prompt a hemolysis workup and senior review. In immune hemolysis, bilirubin level may not correlate well with anemia severity.

5. Measuring Bilirubin: Practical Rules

Measurement Issue	Guideline Approach
Visual inspection	Useful for screening only. Examine sclerae, gums, and blanched skin in good natural light, but do not use appearance to estimate bilirubin severity. Jaundice may be harder to recognize in darker skin.
Transcutaneous bilirubin (TcB)	A noninvasive screening tool for infants ≥35 weeks and >24 hours when clinically appropriate. Confirm with TSB if close to treatment threshold, at device limit, during/after phototherapy per local policy, or if clinical concern is high.
Total serum bilirubin (TSB)	Gold standard for treatment decisions — especially in the first 24 hours, infants <35 weeks, values at/near treatment threshold, rapidly rising bilirubin, illness, or phototherapy/exchange decisions.
Direct / conjugated bilirubin	Check when jaundice is prolonged, stools are pale, urine is dark, the infant is ill, hepatosplenomegaly is present, or cholestasis/metabolic disease is suspected.
Rate of rise	A rapid rise suggests hemolysis or inadequate treatment. NICE flags >8.5 µmol/L/hour; Belize flags ≥0.3 mg/dL/hour over 4–8 hours as concerning. Calculate explicitly when hemolysis is suspected.
Do not subtract direct bilirubin	Treatment decisions for unconjugated hyperbilirubinemia should use total bilirubin; do not subtract the direct/conjugated fraction from TSB when applying treatment charts.

6. Initial Evaluation of a Jaundiced Infant

Scenario	Recommended Workup
All jaundiced infants	Gestational age, postnatal age in hours, bilirubin value and trajectory, feeding adequacy, weight change, urine/stool pattern, family history, maternal blood type/antibody screen, bruising/cephalohematoma, and complete physical examination.
Jaundice in first 24 hr	Urgent TSB with direct/conjugated fraction; infant and maternal blood type; DAT; CBC/Hct; reticulocyte count; smear; and evaluation for hemolysis, infection, birth trauma, and bruising.
Significant or rapidly rising TSB	TSB/direct bilirubin, CBC/Hct, reticulocyte count, DAT, blood group/Rh, antibody screen as needed, smear, albumin if near exchange threshold, G6PD when indicated, and cultures if infection is suspected.
DAT-positive or maternal antibody	Trend bilirubin closely, check Hb/retic, monitor for late anemia, and involve senior neonatology. Kell antibodies may suppress marrow as well as cause hemolysis.
Poor response to phototherapy	Confirm irradiance/device setup (see Chapter 10.7), repeat TSB, assess hydration/feeding, evaluate hemolysis including G6PD, consider sepsis/UTI, and escalate early.
Prolonged jaundice	Term ≥14 days or preterm ≥21 days: stool/urine color, total/direct bilirubin, CBC, mother/baby blood group and DAT, urine culture if indicated, review newborn screen for hypothyroidism/galactosemia, and consider liver/metabolic workup.
Conjugated hyperbilirubinemia	Treat as pathologic. Evaluate for biliary atresia, infection, UTI/sepsis, metabolic disease, endocrine disease, anatomic obstruction, PN-associated cholestasis, and liver synthetic dysfunction. Urgent gastroenterology/hepatology input — biliary atresia is time-sensitive.

7. Differential Diagnosis Organized by Mechanism

Mechanism	Examples and Clues
Immune hemolysis	Rh disease, ABO incompatibility, minor blood group antibodies. Look for positive DAT, maternal antibodies, early jaundice, anemia, and reticulocytosis.
Nonimmune hemolysis	G6PD deficiency, hereditary spherocytosis/elliptocytosis, pyruvate kinase deficiency, congenital erythropoietic porphyria, sepsis/oxidative stress, or mechanical hemolysis.
Increased RBC mass or breakdown	Polycythemia, infant of diabetic mother, delayed cord clamping with high hematocrit, bruising, cephalohematoma, subgaleal hemorrhage, intracranial hemorrhage.
Poor intake / dehydration	Suboptimal breastfeeding, delayed lactogenesis, excessive weight loss, low urine/stool output, hypernatremic dehydration.
Impaired conjugation	Prematurity, hypothyroidism, hypopituitarism, Gilbert syndrome, Crigler-Najjar syndrome, galactosemia, medication effects.
Increased enterohepatic circulation	Delayed stooling, ileus, intestinal obstruction, Hirschsprung disease, cystic fibrosis, pyloric stenosis, or severe illness with poor gut motility.
Cholestatic / conjugated disease	Biliary atresia, neonatal hepatitis, PN cholestasis, sepsis/UTI, TORCH/CMV, alpha-1 antitrypsin deficiency, tyrosinemia, galactosemia, hypothyroidism, hypopituitarism.

8. Prolonged Jaundice and Cholestasis: Safety Pathway

Term infant: visible jaundice beyond 14 days needs evaluation. Preterm infant: visible jaundice beyond 21 days needs evaluation.
Ask directly about pale or chalky stools, dark urine that stains the diaper, poor growth, bleeding, hepatosplenomegaly, hypoglycemia, and acholic stool photographs if available.
Measure direct/conjugated bilirubin — do not assume breast-milk jaundice without it.
If direct/conjugated bilirubin is elevated, discuss urgently with gastroenterology/hepatology because biliary atresia is time-sensitive (Kasai portoenterostomy is most effective before 60 days of life).
Confirm that newborn screening was completed and specifically review congenital hypothyroidism, galactosemia, tyrosinemia, and other local screen results.

Parent-facing message

Tell families that jaundice is common and usually temporary, but jaundice in the first day, poor feeding, sleepiness, high-pitched cry, abnormal tone, pale stools, dark urine, or jaundice persisting beyond 2–3 weeks needs medical review. Breastfeeding usually continues with skilled feeding support.

9. Escalation Triggers Before Chapter 10.7 Treatment Decisions

Escalation Level	Triggers
Immediate senior review	Jaundice <24 hr; TSB at/near treatment threshold; rapidly rising bilirubin; positive DAT with rising bilirubin; suspected hemolysis; preterm infant with high bilirubin; any neurologic symptoms (lethargy, poor suck, high-pitched cry, tone abnormality).
Prepare for intensive treatment	TSB near exchange threshold; bilirubin rising despite appropriate phototherapy; hemolytic disease; low albumin/high neurotoxicity risk; or inability to ensure timely repeat bilirubin measurement.
NICU admission / transfer	Signs of acute bilirubin encephalopathy; exchange-level bilirubin; critical illness; severe hemolysis/anemia; need for IVIG/exchange transfusion; or local unit unable to provide intensive phototherapy and monitoring.
Subspecialty referral	Conjugated hyperbilirubinemia; suspected biliary atresia; liver synthetic dysfunction; metabolic disease; recurrent severe jaundice; suspected RBC membrane/enzyme disorder; or unexplained hemolysis.

10. Source-Difference Notes for Bedside Use

Source	How to Interpret
Baylor 2025–2026	Uses AAP 2022 framing for infants ≥35 weeks; emphasizes BIND terminology, bilirubin mechanisms, risk factors, G6PD consideration, and a clear separation between evaluation (8.4) and management (8.5).
West Midlands 2025–2028	Uses NICE charts and highlights practical rules: do not subtract conjugated bilirubin, monitor bilirubin after phototherapy initiation, and follow hemolytic disease for late anemia.
Belize 2018–2021	Uses older Bhutani/AAP 2004 figures and BAMR material; useful for workup structure and resource-variable settings, but treatment thresholds should be updated locally to current AAP/NICE charts.
Neonatology Academy synthesis	Use current local charts for treatment, but keep a universal safety approach: early jaundice and conjugated/prolonged jaundice are not physiologic diagnoses and require structured evaluation regardless of resource setting.

11. One-Minute Bedside Checklist

Step	Action
1	Confirm gestational age, postnatal age in hours, bilirubin method (TcB vs TSB), and whether treatment thresholds apply to this infant.
2	Ask: jaundice in first 24 hr? rapid rise? poor feeding/dehydration? bruising/hematoma? family history? sibling treated? maternal antibodies?
3	Check for neurotoxicity signs: lethargy, high-pitched cry, poor suck, hypotonia/hypertonia, retrocollis, opisthotonos, apnea, seizures.
4	If significant jaundice: obtain TSB/direct bilirubin, CBC/Hct, retic, DAT, mother/baby blood type, smear, and G6PD or cultures when indicated.
5	If prolonged or direct bilirubin elevated: evaluate stool/urine color and start cholestasis/liver pathway. Do not label as breast-milk jaundice without measuring direct bilirubin.
6	Escalate early if TSB is near exchange threshold, rising despite treatment, hemolysis is suspected, or follow-up cannot be guaranteed.

Key Takeaways — Chapter 10.6

Jaundice in the first 24 hours is pathologic until evaluated — never assume physiologic.
Do not estimate bilirubin severity by skin color; measure TcB and confirm with TSB when near threshold or in clinical doubt.
Do not subtract the conjugated fraction from TSB when applying treatment charts.
Hemolysis can be present without dramatic anemia early — check DAT, retics, smear, and maternal antibodies whenever bilirubin rises faster than expected.
Acute bilirubin encephalopathy: poor feeding/lethargy → irritability/retrocollis → apnea/seizures/coma. Escalate immediately at any stage.
Conjugated hyperbilirubinemia is never physiologic — check direct bilirubin in any infant with jaundice beyond 14 days (term) or 21 days (preterm).
Pale stools + dark urine in a jaundiced infant = biliary atresia until proven otherwise. Refer urgently — Kasai is most effective before 60 days.
Preterm infants (<35 weeks) need local NICU-specific charts; AAP 2022 applies only to ≥35 weeks.
Treatment details (phototherapy thresholds, IVIG, exchange transfusion) are in Chapter 10.7.

Selected References

Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Sections 8.4 Neonatal Jaundice and 8.5 Management of Neonatal Jaundice.
West Midlands Neonatal Operational Delivery Network. Neonatal Guidelines 2025–2028. Blood Group Incompatibilities; Jaundice; Liver Dysfunction; and related hematology guidance.
Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Hyperbilirubinaemia and Conjugated Hyperbilirubinaemia sections.
Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859.
National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days. NICE Guideline CG98, last updated 31 October 2023.
American Academy of Pediatrics. Guidance for the Primary Care Provider in Identifying Infants With Biliary Atresia. Pediatrics. 2025;155(3):e2024070077.

Clinical governance note

This is an educational guideline synthesis. Use local hour-specific, gestation-specific bilirubin charts and local blood bank/phototherapy policies for patient care decisions.